Pharmala Biotech Holdings Inc

Pharmala Biotech’s new drug‑donation deal with Spaulding Rehabilitation could pivot it from oncology to fibromyalgia, testing LaNeo™ MDMA’s pain‑relief potential in a high‑stakes, psychedelic‑therapy‑era market.

Pharmala Biotech Holdings Inc. reports a CAD 0.10 stock price and negative P/E, spotlighting its oncology drug pipeline, modest volatility, and partnership strategy.

Pharmala Biotech’s board reshuffle brings seasoned accountant Lennie Ryer to bolster governance and support its oncology‑focused drug‑development strategy, aiming for stronger growth and breakthrough cancer therapies.

Pharmala Biotech: Canadian oncology‑focused biotech with strong IP, yet negative earnings and low share price. Learn why investors watch its next move.

Pharmala Biotech, a Canadian oncology biotech, advances breakthrough cancer therapies despite a negative P/E, building a strong IP portfolio and partnership strategy.

Pharmala Biotech: Canadian biotech focused on oncology drug discovery and commercialization, offering breakthrough therapies and strategic partnerships to improve patient outcomes.

Pharmala Biotech: Canadian biotech leader in oncology, innovating breakthrough cancer therapies, strong R&D pipeline, and strategic collaborations for patient‑centric impact.

Pharmala Biotech’s successful release testing of its first Australian LaNeo MDMA 40 mg batch marks a major production milestone, boosting its oncology pipeline and global growth plans.

Pharmala Biotech: Canadian oncology‑focused biotech driving breakthrough cancer therapies, building IP, partnerships, and sustainable growth for patient outcomes.

Pharmala Biotech Holdings Inc (PHLM) is a tiny Canadian biotech focused on oncology, trading at CAD 0.10 with a CAD 12 m market cap and a negative P/E—an overview of its precarious finances and high‑risk investment profile for speculative traders.